SurModics IVD to Launch New Product at AACC in Los Angeles, CA

July 9, 2012 at 8:00 AM EDT

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 9, 2012-- SurModics IVD Inc., a wholly owned subsidiary of SurModics, Inc. (Nasdaq: SRDX) and a market leader for in vitro diagnostic assay components, is pleased to announce it will launch BioFX® TMB Extended Range HRP Microwell Substrate (TMBX) at the American Association for Clinical Chemistry show in Los Angeles, CA from July 17-19, 2012.

Use of BioFX TMBX in a quantitative assay (i) can increase the assay's upper limit of quantitation and (ii) maintain the detection limits and analytical sensitivity achieved with other SurModics TMB substrates. TMBX also improves the reproducibility of the assay through lower backgrounds and better control of assay timing. TMBX is our slowest kinetic option of TMB substrates for extended dynamic range and improved reproducibility within.

“This newest addition to SurModics’ line of TMB substrate products further demonstrates the flexibility of our capabilities to support the in vitro diagnostics industry and its extended dynamic range needs,” said Gary Maharaj, president and chief executive officer of SurModics. “SurModics is committed to using its diagnostic history and expertise to develop and improve products, including custom formulation options to better serve our customers.”

To learn more about SurModics'in vitro diagnostic products, please visit our website (, or contact customer service at 952-500-7200 or SurModics IVD now offers easy online ordering of over 900 IVD products available at SurModics is a registered trademark of SurModics, Inc.

About SurModics, Inc.
SurModics' mission is to exceed our customers' expectations and enhance the well-being of patients by providing the world's foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world's leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include (i) surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities, and (ii) components for in vitro diagnostic tests and microarrays. SurModics is headquartered in Eden Prairie, Minnesota. For more information about the Company, visit The content of SurModics' website is not part of this release or part of any filings the Company makes with the SEC.

Source: SurModics, Inc.

SurModics, Inc.
Tim Arens, vice president of finance and interim chief financial officer